Zoom brings together in-office and remote employees with the launch of Intelligent Director for Zoom Rooms

AI-powered Intelligent Director enhances connection and optimizes the conference room experience for hybrid work, using multiple cameras to give every participant their own space in Zoom Meetings

SAN JOSE, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Today Zoom Video Communications, Inc. (NASDAQ: ZM) announced the launch of the award-winning Intelligent Director for Zoom Rooms. For hybrid meetings with a Zoom Room, Intelligent Director uses AI and multiple cameras to provide the best image and angle of participants in the room so remote participants can see each person clearly, even in large conference rooms.

“As more people return to the office, it’s no longer enough to deliver the best remote worker experience; every business needs a solution to deliver the best hybrid meeting experience,” said Smita Hashim, chief product officer at Zoom. “Even with some employees in the office, oftentimes other team members are dispersed, so meeting equity and inclusion become more important than ever. Intelligent Director is the solution that can bring employees together, regardless of location, so they can truly connect face-to-face.”

Intelligent Director is specifically designed for medium- to larger-sized rooms and helps avoid the “bowling alley effect.” Intelligent Director can individually frame up to 16 participants in a Zoom Room using multiple cameras, choosing the best video stream via a Zoom-designed AI, and send that stream to the gallery view of the Zoom Meeting.

An evolution of Zoom’s Smart Gallery feature, which uses a single camera and AI to give each person in a small to medium-sized room their own space in a Zoom Meeting, Intelligent Director takes this same technology to the next level for larger conference rooms.

For bigger meeting spaces, it is easier to be hidden by others when only using a single camera, so Intelligent Director’s multi-camera configuration and use of video AI technology provide meeting equity to everyone in the room, selecting the best view of each individual, even if they move around or turn their heads. Remote participants can now have face-to-face conversations with each Zoom Rooms participant, allowing in-room participants to be seen and heard.

Intelligent Director is made possible through the support of Zoom’s hardware partner ecosystem. Manufacturers, including Apple, AVer, Dell, HP | Poly, Intel, Logitech, and Yealink have supported Zoom with the computer, controller, and camera solutions necessary to produce this major advancement.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Lacretia Taylor
press@zoom.us

GlobeNewswire Distribution ID 8865322

IAVI Starts First-in-Human Phase I Clinical Trial of Single-Dose Sudan Virus Vaccine Candidate

NEW YORK, NY / ACCESSWIRE / June 27, 2023 / IAVI announced today that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase I clinical trial in the U.S. The IAVI-sponsored trial is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

Known as IAVI C108, this first-in-human study is designed to evaluate the safety and immunogenicity of an investigational SUDV vaccine candidate donated to IAVI by Merck (known as MSD outside the U.S. and Canada) to supplement IAVI’s ongoing SUDV vaccine development program. This investigational SUDV vaccine candidate was produced for IAVI from existing investigational bulk drug substance previously manufactured by Merck. IAVI is the vaccine candidate’s regulatory sponsor. IAVI is responsible for all aspects of the candidate’s future development, including demonstrating equivalence between this SUDV vaccine candidate and IAVI’s other SUDV vaccine candidate, which utilizes the same viral vector but is manufactured using a new production platform.

The SUDV vaccine candidate being evaluated in IAVI C108 uses the same recombinant vesicular stomatitis virus (rVSV) viral vector platform as ERVEBO®, Merck’s single-dose Zaire ebolavirus (ZEBOV) vaccine which is licensed in the U.S., U.K., European Union, Canada, Switzerland, and 10 African countries. rVSV is also the platform technology utilized in IAVI’s portfolio of emerging infectious disease (EID) candidates.

“IAVI C108 represents an important first step toward generating the data needed for eventual licensure of an rVSV-SUDV vaccine. The development and licensure of ERVEBO® has resulted in an important tool in Ebola Zaire outbreak response. If proven effective, we’re hopeful that a vaccine candidate built on the same viral platform will be similarly important in future SUDV outbreaks,” said Swati Gupta, Ph.D., vice president and head of emerging infectious diseases and epidemiology at IAVI. “In parallel, we must continue accelerating efforts toward the adequate availability of candidate vaccine doses for evaluation during and ahead of outbreaks with key partners, collaborators, and funders. We’re grateful to Merck for donating the doses that will be used in IAVI C108 and to BARDA for its support of this trial.”

IAVI C108 will take place at two U.S.-based clinical trial sites, where the study vaccine will be administered intramuscularly at three dosage levels. This is a placebo-controlled, single-blind study, meaning that only the researchers conducting the study will know whether a participant has received a vaccine dose or a placebo dose until after the trial is over. Approximately 36 healthy adults will be enrolled and will be followed for six months after vaccination to monitor their safety and immune responses to the vaccine candidate.

Like ZEBOV, SUDV is responsible for recurring viral hemorrhagic fever outbreaks, which have had lasting impacts on health security and geopolitical stability across sub-Saharan Africa. The estimated case fatality ratios of SUDV disease have varied from 41% to 100% in past outbreaks[1]. Despite high morbidity and mortality, there are no vaccines or therapeutics licensed for the prevention and treatment of SUDV. Existing ZEBOV vaccines and treatments are not effective against SUDV. Data being generated from ongoing studies suggest that rVSV could be a safe and effective platform for responding to SUDV and other related pathogens[2].

IAVI’s rVSV-based EID portfolio includes a SUDV vaccine candidate supported by BARDA; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations and the European & Developing Countries Clinical Trials Partnership; a Marburg virus vaccine candidate supported by BARDA and the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD); and an intranasal SARS-CoV-2 vaccine candidate supported by DOD DTRA and the Japan Ministry of Finance.

The rVSV platform has been used extensively in adults and children[3]. The underlying vesicular stomatitis virus (VSV) is a common animal virus that does not cause serious illness in humans and has been investigated extensively as a vaccine vector. In the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – to prompt the body to mount an immune response.

Much of the research and development on IAVI’s rVSV platform is performed at the IAVI Vaccine Design and Development Lab (DDL) in Brooklyn, New York. The DDL is located at the bioscience center in the historic Brooklyn Army Terminal. Since its founding in 2008, the IAVI DDL has become one of the world’s leading viral vector vaccine research and development labs, known for innovation and generation of novel vaccine design concepts.

Scientists with IAVI’s Human Immunology Laboratory (HIL) in London, U.K., are involved in processing participant samples and developing the analytical assays needed to evaluate IAVI C108 participants’ immune responses. Established in 2001, the HIL is fully integrated into the Infectious Disease department within the Faculty of Medicine at Imperial College London and serves as the clinical immunology reference laboratory for IAVI and the network of clinical research centers with which IAVI collaborates worldwide.

Media Contact
Rose Catlos
Rcatlos@iavi.org
212-847-1049

About IAVI
IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Follow IAVI on Facebook, LinkedIn, Instagram, and YouTube, and subscribe to our news updates.

About IAVI’s rVSV vaccine candidates
IAVI holds a nonexclusive license to the rVSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

IAVI initially developed its rVSV vector for HIV vaccine candidates and has since expanded its use to the development of vaccines addressing emerging infectious diseases (Lassa Fever, Marburg, Sudan ebolavirus, and COVID-19).

Funders who have made the development of IAVI’s rVSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health; and through the generous support of the American people from the United States Agency for International Development.

This project is funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract number 75A50121C00077.

[1] https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON410

[2] https://link.springer.com/article/10.1007/s11262-017-1455-x

[3] https://cdn.who.int/media/docs/default-source/blue-print/who-vaccine-prioritization-report-uganda-ebola-trial-nov-16-2022.pdf

SOURCE: IAVI

Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice

Leading Breast Pump Brand Hosts Global Event to Advance Breastfeeding Research and Understand Current Hospital-Based Practices, Sharing Research Findings Free of Charge

Switzerland, Baar, June 27, 2023 (GLOBE NEWSWIRE) — Medela, the brand trusted by millions of moms*, concluded its 16th Global Breastfeeding and Lactation Symposium, focused on advancing lactation science to improve care. This three-part world tour was held in three locations, kicking off in Chicago, Illinois in April, followed by Beijing, China in May, and concluding in Munich, Germany in June. All three events welcomed more than 2,600 healthcare professionals in maternal and infant care to learn about the latest research findings and key insights from globally and regionally renowned experts in human milk and lactation. Delivering on Medela’s commitment of turning science into care, speaker presentations from the series will be available free of charge for virtual access through Medela University from next week.

“By bringing together top minds in lactation science from around the world, we are able to further our shared goal of improving maternal and infant health outcomes,” said Annette Brüls, CEO of  Medela worldwide. “We know that conducting the research is only half of a much larger picture, which is why our Global Symposium is committed to creating a dynamic learning opportunity to transfer this knowledge from the experts in science and research to the leaders in healthcare settings around the world. We are bridging the gap between research and practice, making it accessible, free of charge, to the people who use and need it, with the sole intention of nurturing health for generations.”

The global event featured presentations and discussions from experts, including:

PROF. LARS BODE (USA) | Lactation as a biological system: The dynamics of human milk composition

“Human milk and lactation do not stand in isolation; they are part of a dynamic biological system that is embedded in socioeconomic, cultural, behavioral, and environmental contexts,” explains Professor Bode, Ph.D., at the University of California San Diego. “As a scientist, it was exciting to participate in Medela’s Breastfeeding & Lactation Symposia because the events connect the science with the clinical application of human milk and lactation, which together is a major driver to advance the field with maximum impact on infant health and development.”

PROF. DONNA GEDDES (AU) | Lactation as a biological system: The importance of dose

“As we seek to understand how human milk composition impacts the health of our next generation, we often default to analyzing concentrations of milk components. Yet when we measure the dose the baby receives, a new world opens up with the promise of innovative ways to improve the health of our children,” says Professor Geddes from the University of Western Australia. “I appreciate the opportunity to share my scientific findings at this stellar conference, but I find the interaction with the participants invaluable, as they come from all disciplines essential to improving breastfeeding and breast milk delivery for all lactating women and their babies.”

DR. REBECCA HOBAN (CA) | Initiation of lactation: Prophylactic lactation support as standard of care for mothers of NICU infants

“Although we know that mother’s milk is literally lifesaving for preterm infants in the NICU, many mothers struggle to make enough milk for their babies, limiting their infant’s lifelong milk dose and it is my passion to optimize lactation for these vulnerable families,” shares Dr. Hoban, staff neonatologist and Director of Breastfeeding Medicine at The Hospital for Sick Children in Toronto. “Medela’s Symposium brings new lactation evidence to clinician leaders who will translate the science to the bedside for families around the world. It’s a great way to ‘spread the word’ about the latest findings in breastfeeding research!”

PROF. DIANE SPATZ (USA) | A call to action: Improving human milk and breastfeeding outcomes by prioritizing effective initiation of lactation

“There is a critical window for the establishment of a milk supply and, we as advocates and clinicians have an obligation to families to teach them the science of human milk and the physiology of lactation,” explains Professor Diane Spatz, who also serves as chairperson for Medela’s Scientific and Clinical Advisory Board in the Americas. Prof. Spatz presented a call to action about the need for prioritizing effective initiation of lactation in order to improve exclusivity and duration of breastfeeding. Prof. Spatz is a Professor of Perinatal Nursing at the University of Pennsylvania School of Nursing sharing a joint appointment at Children’s Hospital of Philadelphia.

Held as a hybrid event in Beijing on May 13-14, the China Symposium focused on providing a platform for like-minded breastfeeding professionals to share ideas, experiences and best practices. In partnership with the China Maternity and Child Health Association, the event marked a shared commitment to educating individuals on the benefits of human milk, while strengthening the collective efforts to foster a supportive environment for breastfeeding in China.

PROF. CAO YUN (CHINA) | The impact of human milk feeding on the outcomes of NICU premature infants based on clinical research in China

”As an experienced NICU physician, I have been promoting human milk feeding since I learned of its benefits for NICU infants. I am pleased to see so many obstetrics, pediatrics, and nursing experts gathered here. The promotion of breastfeeding cannot be achieved without the cooperation of various departments and multi-disciplinary teams.” says Prof. Cao Yun from Fudan University Children Hospital. “It is great that Medela organizes such an informative symposium that allows us to unite to promote breastfeeding in China.”

PROF. YU HONG (CHINA) Quality improvement study on breastfeeding in mother-infant-separation dyads after standardized interventions

“I was very excited to participate in this grand event organized by Medela and learned about global cutting-edge research,” says Prof. Yu Hong from Southeast University Zhongda Hospital. “I led a multiple-center quality improvement study in Jiangsu Province, and our objective is to support lactation and improve the dose of own mother’s milk feeding through the evidence-based interventions.”

PROF. FENG QI (CHINA) Clinical study on promoting breastfeeding of premature infants in China

“Breastfeeding is not only a mother’s business, but also depends on family and social support,” says Prof. Feng Qi from Peking University First Hospital. “At present, the government has issued documents to support breastfeeding, and we also have the consensus from professional groups. As more and more hospitals are paying increasing attention to breastfeeding, we need to proactively adopt best clinical practices to improve breastfeeding in the NICU.”

DR. YUKI TAKAHASHI (JAPAN) | Effect of epidural analgesia on infant sucking and opportunities for improvement to achieve the standard of care for infants

“Intrapartum interventions such as epidural analgesia or induction of labor can influence skin-to-skin contact and rooting/suckling behavior, not only right after, but up to two days after birth,” says Dr. Yuki Takahashi from Nagoya University Japan. “And the important thing is to prioritize breastfeeding support resources to provide behaviorally appropriate and individualized care during this critical period.”

On June 23-24, Medela hosted the European Edition of their world tour in Munich, Germany, and welcomed two internationally renowned British speakers who shared their insights for improving lactation support in the neonatal intensive care unit. On day two of the symposium the healthcare experts on-site took these findings into curated workshops with the goal of translating them into clinical practice.

PROF. NEENA MODI (UK) | Perspectives: Prioritizing own mother´s milk in the neonatal unit – need for standardized metrics that capture lactation and infant feeding

“Prioritizing the provision of own mother’s milk (OMM) is a crucial step in neonatal care and thorough, high-quality data on lactation and infant feeding are fundamental in assessing the success of OMM provision and understanding the extent to which infants leave the neonatal unit breastfeeding,” asserts Professor Neena Modi of the Imperial College London, who also serves as President-elect of the European Association of Perinatal Medicine. Prof. Modi underscored that by implementing standardized information recording in neonatal units, we can develop universally accepted quality indicators, improve care, and drive research for better breastfeeding outcomes.

DR. SARAH BATES (UK) | Spotlight: Improving survival & outcomes for preterm infants through optimizing early maternal breast milk – a national Quality Improvement toolkit from BAPM

“Optimizing own mother’s milk (OMM) is crucial for the long-term health of preterm infants,” explained Dr. Sarah Bates, Consultant Pediatrician and Neonatologist at the Great Western Hospital in Swindon. In her talk Dr. Bates shed light on the innovative national toolkits created by the British Association of Perinatal Medicine, demonstrating its utility in optimizing OMM for preterm infants from initiation of lactation to post-discharge. Her session, infused with success stories and insightful parental views, showcased how this initiative can positively reshape the health trajectories of preterm infants nationwide.

Turning science into care

Presentations from speakers will be available free of charge for virtual access through Medela University, an online professional education platform for lactation science offering continuing education units (CEUs).

In addition, Medela will host a series of educational webinars in the US and Europe to translate existing research findings into clinical practice and share important conclusions and expert recommendations. While the US webinars will focus primarily on disparities in breastfeeding and resources for clinicians to assess their own implicit bias and alter clinical practice to better support Black women who breastfeed, the European webinars will focus on improving lactation science and improving care in neonatal units.

Learn more about the Global Breastfeeding and Lactation Symposium at medela.com/symposium.

Media resources, including language versions of the press releases and visual assets are available for download at medela.com/symposium-media.

About Medela

Through advancing research, observing natural behavior, and listening to our customers, Medela turns science into care while nurturing health for generations. Medela supports millions of moms, babies, patients, and healthcare professionals in more than 100 countries all over the world. As the healthcare choice for more than 6 million hospitals and homes across the globe, Medela provides leading research-based breast milk feeding and baby products, healthcare solutions for hospitals, and clinical education. Medela is dedicated to building better health outcomes, simplifying and improving life, and developing breakthroughs that help moms, babies and patients live their life to the fullest. For more information, visit www.medela.com.

* Medela global sales, 2022

Attachments

Media Office
Medela
Media.Inquiries@medela.com

GlobeNewswire Distribution ID 8865260

Bybit Granted MVP License from Dubai’s Virtual Assets Regulatory Authority

DUBAI, UNITED ARAB EMIRATES – Media OutReach – 27 June 2023 – Bybit FinTech FZE, a subsidiary of Bybit, a global leading crypto exchange, announced today that it has been granted the Minimum Viable Product (MVP) Preparatory License by Dubai’s Virtual Assets Regulatory Authority (VARA), following the Provisional License it received in March 2022.

The Preparatory License does not yet allow Bybit to commence virtual asset operations in the Emirate of Dubai, but exhibits the significant progress made to obtain operational permission from VARA.

“We would like to express our gratitude to VARA for their careful consideration of our application and for granting us the MVP Preparatory License. This is a crucial step forward for Bybit in the UAE, as Dubai plays a pioneering role in advancing the world’s development of financial innovation and digital assets,” said Ben Zhou, co-founder and CEO of Bybit. “We consider the receipt of this license to be a significant milestone that acknowledges the hard work, dedication, and strong commitment to compliance exhibited by our team.”

#Bybit / #TheCryptoArk / #BybitPartners

More From Bybit

About Bybit

Bybit is a cryptocurrency exchange established in 2018 that offers a professional platform where crypto traders can find an ultra-fast matching engine, excellent customer service and multilingual community support. Bybit is a proud partner of Formula One’s reigning Constructors’ and Drivers’ champions, the Oracle Red Bull Racing team, esports teams NAVI, Astralis, Alliance, Made in Brazil (MIBR), and Oracle Red Bull Racing Esports, and association football (soccer) team Borussia Dortmund.

For more information please visit: https://www.bybit.com/

For updates, please follow: Bybit’s Communities and Social Media

https://discord.com/invite/bybit
https://www.facebook.com/Bybit
https://www.instagram.com/bybit_official/
https://www.linkedin.com/company/bybitexchange/
https://www.reddit.com/r/Bybit/
https://t.me/BybitEnglish
https://www.tiktok.com/@bybit_official
https://twitter.com/Bybit_Official
https://www.youtube.com/c/Bybit

For media inquiries, please contact: press@bybit.com

About VARA

Dubai Virtual Assets Regulatory Authority [VARA] is the world’s first specialised regulator for the Virtual Assets sector. Established in March 2022, following the effect of Law No.4 of 2022, VARA is the competent entity in charge of regulating, supervising, and overseeing VAs and VA Activities in all zones across the Emirate of Dubai, including Special Development Zones and Free Zones but excluding the Dubai International Financial Centre. VARA plays a central role in creating Dubai’s advanced legal framework to protect investors and establish international standards for Virtual Asset industry governance, while supporting the vision for a borderless economy.

Bybit Secures License to Operate Cryptocurrency Exchange and Custody Services in Cyprus

DUBAI, UNITED ARAB EMIRATES – Media OutReach – 26 June 2023 – Bybit, the world’s third most visited crypto exchange, is pleased to announce that it has successfully obtained a license to operate a crypto exchange and provide custody services in Cyprus. This milestone demonstrates Bybit’s commitment to working within regulatory frameworks and providing its users with secure and compliant trading solutions.

Bybit’s newly acquired license from the regulatory authorities in Cyprus allows the company to offer a full suite of services, including trading between crypto pairs and fiat currency pairs, financial services related to crypto assets, and custody solutions tailored to clients in Cyprus and E.U. member states. With this license, Bybit establishes itself as a trusted and regulated platform within the Cyprus cryptocurrency market.

Cyprus is recognized as a burgeoning hub for cryptocurrency activities, with a growing community of crypto enthusiasts and a favorable regulatory environment. Bybit recognizes the immense potential of the Cyprus market and is excited to bring its next-level reliability and opportunities to the local digital asset community.

“At Bybit, we wholeheartedly support the regulatory objective of building a cryptocurrency industry that is both compliant, secure, and transparent, ultimately benefiting all those seeking financial freedom,” said Ben Zhou, co-founder and CEO of Bybit. “This landmark is a testament to Bybit’s commitment to adhering to robust regulatory frameworks while expanding our global presence. We look forward to bringing the Crypto Ark to Cyprus.”

Bybit has a sterling reputation for digital asset security, compliance, and protection. Due in no small part to its enhanced KYC and AML procedures, successfully obtaining the ISO 27001:2013 certification for its robust security management system, and running real-time, on-chain, proof-of-reserves data with a purpose-built Merkle tree.

More From Bybit

#Bybit / #TheCryptoArk

About Bybit

Bybit is a cryptocurrency exchange established in 2018 that offers a professional platform where crypto traders can find an ultra-fast matching engine, excellent customer service and multilingual community support. Bybit is a proud partner of Formula One’s reigning Constructors’ and Drivers’ champions, the Oracle Red Bull Racing team, esports teams NAVI, Astralis, Alliance, Made in Brazil (MIBR), and Oracle Red Bull Racing Esports.

For more information please visit: https://www.bybit.com/

For updates, please follow: Bybit’s Communities and Social Media

https://discord.com/invite/bybit
https://www.facebook.com/Bybit
https://www.instagram.com/bybit_official/
https://www.linkedin.com/company/bybitexchange/
https://www.reddit.com/r/Bybit/
https://t.me/BybitEnglish
https://www.tiktok.com/@bybit_official
https://twitter.com/Bybit_Official
https://www.youtube.com/c/Bybit

For media inquiries, please contact: press@bybit.com

SAP Fioneer lança produto bancário personalizado para PMEs

WALLDORF, Alemanha, June 27, 2023 (GLOBE NEWSWIRE) — A SAP Fioneer, fornecedora líder global de soluções e plataformas de software de serviços financeiros, anunciou o lançamento de sua Fioneer SME Banking Edition. A solução permitirá que bancos e neobancos ofereçam recursos bancários em uma abordagem digital e orientada por dados, adaptada às necessidades financeiras de pequenas e médias empresas (PMEs) – um segmento de mercado historicamente carente.

O setor das PMEs é um componente vital da economia global, representando 99% das empresas do Reino Unido e da UE e empregando cerca de 16,4 milhões e 84 milhões de pessoas, respectivamente.* Apesar de representarem uma proporção significativa do PIB e da mão de obra, as PMEs têm tradicionalmente lutado para aceder a serviços financeiros que satisfaçam as suas necessidades específicas, uma vez que os riscos e custos associados percebidos são considerados demasiado elevados.

A Fioneer SME Banking Edition aborda esses desafios conectando bancos a fontes de dados externas, como Open Banking, registro central de empresas, comércio eletrônico e dados de Enterprise Resource Planning (ERP), para produzir informações úteis que ajudam significativamente as PMEs a se manterem na vanguarda. Isso proporcionará às PMEs uma elevada transparência quanto ao fluxo de caixa e fornecerá informações aos bancos, permitindo, por exemplo, opções de financiamento inteligentes, oferecendo mais variedade e aumentando o número de empresas que os bancos podem atender.

Como uma solução única de ponta a ponta, a Fioneer SME Banking Edition abrange recursos front-to-back e se integra perfeitamente a qualquer sistema bancário central. Ele permite que os bancos ofereçam serviços que vão além dos produtos bancários tradicionais, como empréstimos e depósitos. Os bancos poderão ampliar sua oferta com serviços integrados e aconselhamento financeiro mais sólido diretamente para as PMEs. A solução também pode ser facilmente integrada e conectada a ecossistemas por meio de APIs pré-configuradas.

Charlie Platt, Diretor Executivo de Bancos da SAP Fioneer, comenta sobre o lançamento: “As PMEs representam a força vital da economia e é fundamental que elas possam acessar os serviços financeiros que merecem. Através da nossa SME Banking Edition, os bancos poderão criar experiências bancárias comercialmente viáveis, exclusivas e melhores para as PMEs que as ajudarão a manter-se na vanguarda em um ambiente económico desafiador.”

“O lançamento da nossa Fioneer SME Banking Edition reforça significativamente a forma como os bancos interagem com as PMEs. Utilizando nossa tecnologia comprovada, estamos ajudando os bancos a atenderem melhor as PMEs em um cenário econômico dinâmico. Inspirando-nos no mercado B2C, estamos capacitando os bancos a aumentar suas ofertas de serviços para PMEs”, acrescenta Dirk Kruse, CEO da SAP Fioneer.

*Estimativas da população empresarial para o Reino Unido e regiões 2022 (Governo do Reino Unido), Statista 2022

Sobre a SAP Fioneer

A SAP Fioneer foi lançada em 2021 como uma joint venture entre a líder global de tecnologia SAP e o investidor empreendedor Dediq para se tornar a fornecedora líder mundial de soluções e plataformas de software para serviços financeiros. Com um amplo ecossistema de parceiros, mais de 800 clientes de serviços financeiros e mais de 1.000 funcionários, a SAP Fioneer é uma empresa global presente em 17 países na Europa, América do Norte e Latina, Oriente Médio e Ásia-Pacífico.

Ao combinar a velocidade e a agilidade de uma start-up com os recursos comprovados de uma empresa de software de primeira linha, a SAP Fioneer permite que bancos, seguradoras e concorrentes executem, transformem e cresçam enquanto atendem às suas necessidades de velocidade, escalabilidade e eficiência de custos por meio de inovação de negócios digitais, tecnologia em nuvem e soluções que cobrem processos bancários e de seguros de ponta a ponta.

Para mais informações, visite www.sapfioneer.com Siga a SAP Fioneer no Twitter e no LinkedIn.

Informações para a imprensa:
press@sapfioneer.com

GlobeNewswire Distribution ID 1000827118